FLASH Study: Fluorescent Light Activated Synthetic Hypericin
Soligenix has completed recruiting patients into this Phase 3 study with sites in the US.
A Pivotal Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma (CTCL).
The purpose of this study is to evaluate the use of SGX301, a novel topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides). We enrolled approximately 160 subjects in total.
Topline results indicate that 40% of patients responding to SGX301 treatment after only 12 weeks of treatment (p<0.0001). No concerning safety signals were noted. Follow-up visits are ongoing and expected to be complete in 4Q 2020.
Learn more about SGX301 trial on ClinicalTrials.gov.